SuperworthRapport Therapeutics shares outstanding RAPP
Diluted shares outstanding, averaged over each quarter, from 2023.
- Latest quarter, to Jun 30, 2026
- 47.5M
- On a year earlier
- +33.9%
- more shares
Rapport Therapeutics had 47.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 33.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 47M | +34% |
| FY2024 | 35.1M | +1979% |
| FY2023 | 1.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 47.5M | +34% | |
| Q1 FY26 | 47.2M | +34% | |
| Q4 FY25 | 47M | +34% | |
| Q3 FY25 | 37.9M | +9% | |
| Q2 FY25 | 35.4M | +232% | |
| Q1 FY25 | 35.3M | +1623% | |
| Q4 FY24 | 35.1M | +1979% | |
| Q3 FY24 | 34.9M | +2179% | |
| Q2 FY24 | 10.7M | +641% | |
| Q1 FY24 | 2M | +50% | |
| Q4 FY23 | 1.7M | n/a | |
| Q3 FY23 | 1.5M | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Rapport Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.